СПИСОК ЛИТЕРАТУРЫ

  1. Yokota Т., Suzuki E., Arai К. TE-031 (A-56268), a new macrolide, its in vitro antibacterial activity, synergy of bactericidal effect with serum complement and mouse cultured macrophages, and incorporation into leucocytes. Chemotherapy, 1988, 36: 59-70.
  2. Takeda H., Miura H., Kawahira M., et al. Long-term administration study on TE-031 (A-56268) in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi, 1989, 63: 71-78.
  3. Ohyama M., Furuta S., Fukuda K., et al. Clarithromycin therapy for chronic sinusitis - basic and clinical studies. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 9.14.
  4. Tamaoki J., Takeyama K., Tagaya E., et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob. Agents Chemother., 1995, 39: 1688-1690.
  5. Tamaoki J., Kohri K., Kondo M., et al. Clarithromycin inhibits induction of NOS and NO release from alveolar macrophages. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3024.
  6. Chu S.-Y., Deaton R., Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother., 1992, 36: 1147-1150.
  7. Gan V.N., Chu S.Y., Kusmiesz H.T., et al. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob. Agents Chemother., 1992, 36: 2478-2480.
  8. Stamler D. Pharmacokinetics of a new once-daily formulation of clarithroinycin. In: The 20th International Congress of Chemotherapy. Abstracts of symposium Innovations in Macrolide Therapy. Sydney, 1997: 5.
  9. Suwa Т., Yoshida H., Kohno Y., et al. Metabolic fate of TE-031 (A-56268) III: absorbtion, distribution and excretion of 14C-TE-031 in rats, mice and dogs. Chemotherary, 1988, 36: 213-226.
  10. Chu S.-Y., Wilson D.S., Deaton R.L., et al. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. din. Pharmacol., 1993, 33: 719-726.
  11. Giamarellou H., Koratzanis G., Palaskas L., et al. Clarithromycin pharmacokinetics in the prostatic adenoma tissue of patients undergoing prostatectomy: a preliminary report. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 203.
  12. Gustavson L.E., Craft J.C. Pharmacokinetic prophile of clarithromycin suspension for children: an overview. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 187.
  13. Carr R.A., Gustavson L.E., Palmer R.N., et al. Penetration of clarithromycin into middle ear fluid after multiple doses of clarithromycin suspension to pediatric patients with acute otitis media. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.04.
  14. Langtry H.D., Brogden R.N. Clarithromycin - a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs, 1997, 53: 973-1004.
  15. Kees F., Wellenhofer M., Grobecker H. Serum and cellular pharmacokinetics of clarithroinycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection, 1995, 23: 168-172.
  16. Gotfried M.H., Morris D., Palmer R., et al. Meta-analysis of bronchopulmonary concentrations of clarithroinycin, 14-OH clarithromycin, azithromycin and erythromycin at steady state in normal healthy adults. In: The 20th International Congress of Chemotherapy. Sydney, 1997: abstr. 3026.
  17. Rodvold K.A., Gotfried M.H., Danziger L.H., et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother., 1997, 41: 1399-1402.
  18. Sedlmayr Т., Peters F., Raasch W., et al. Clarithromycin - pharmacokinetics, clinical effectiveness transmission into breast milk of a new macrolide antibiotic in patients with puerperal infections. Geburtshilfe. Frau-enheilkd, 1993, 53: 488-491.
  19. Ferrero J.P., Bopp B.A., Marsh K.C., et al. Metabolism and disposition of clarithromycin in man. Drug Metabol. Disposit., 1990, 18: 441-446.
  20. Davey P.G. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect., 1991, 19 (suppl. A): 29-37.
  21. Hardy D.J., Guay D.R.P., Jones R.N. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagn. Microbiol. Infect. Dis., 1992, 15: 39-53.
  22. Coles S.J., Macklin J.M., Humphreys J.M., et al. Safety and efficacy of clarithromycin confirmed in large adult and pediatric UK population. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 14.05.
  23. Guay D.R.P., Patterson D.R.,Seipman N.,et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf., 1993, 8: 350-364.
  24. Wallace R.J., Brown B.A., Griffit D.E. Drug intolerance to high dose clarithromycin among elderly patients. Diagn. Microbiol. Infect. Dis., 1993, 16: 215-221.
  25. Pichotta P., Gupta S., Prokocimer P., et al. The overall safety of oral clarithromycin in comparative clinical studies. In: The 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
  26. Zimmermann T., Riedel K.-D., Laufen H., et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: A82.
  27. Griffith D.E., Brown B.A., Girard W.M., et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis., 1995, 21: 594-598.
  28. Gustavson L.E., Kaiser J.F., Edmonds A.L., et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother., 1995, 39: 2078-2083.
  29. Mainz D., Borner K., Koeppe P., et al. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. A-120a.
  30. Carr R.A., Gustavson L.E., Palmer R.N., et al. Pharmacokinetic and pharmacodynamic interaction potential between clarithromycin and loratadine. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.32.
  31. Lindquist M., Edwards R. Risks of non-sedating antihistamines. Lancet, 1997, 349: 1322.
  32. Paar D., Terjung B., Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet, 1997, 349: 326-327.
  33. Midoneck S.R., Etingin O.R. Clarithromycin-related toxic effects of digoxin (letter). N. Engl. J. Med., 1995, 333: 1505.
  34. Vance E., Watson-Bitar M., Gustavson L., et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother., 1995, 39: 1355-1360.
  35. Amsden G.W. Review of the comparative pharmacokinetics of the new macrolides and azalide. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.13.
  36. Scrock C.G. Clarithromycin vs penicillin in the treatment of streptococcal pharyngitis. J. Fam. Pract., 1992, 35: 622-626.
  37. Dubois J., Saint-Pierre C. Safety and efficacy of clarithromycin and amoxicillin in the treatment of patients with acute maxillary sinusitis. In: The 17th International Congress of Chemotherapy. Berlin, 1991.
  38. Karma P., Pukander J., Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur. J. Clin. Microbiol. Infect. Dis., 1991, 10: 856-859.
  39. Marchi E. Comparative efficacy and tolerability of clarithromycin and amoxicillin in the treatment of out-patients with acute maxillary sinusitis. Cur. Med. Res. Opin., 1990, 12: 19-24.
  40. Saint-Pierre E., Dubois J., Prokocimer P., et al. An evaluation of clarithromycin and amoxicillin/clavulanate for the treatment of acute maxillary sinusitis. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992.
  41. Gehanno P., Chauvin J.P., Hazebroucq J. Clarithromycin versus amoxicillin-clavulanic acid in acute maxillary sinusitis in adults. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 428-434.
  42. Dubois J., Devcich K. Clarithromycin in the treatment of acute maxillary sinusitis. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 236.
  43. Goumas P., Naxakis S., Bassaris C., et al. Comparative efficacy and tolerability of clarithromycin and cefaclor in the treatment of outpatients with acute maxillary sinusitis. Clin. Drug. Invest., 1997, 13: 128-133.
  44. Hashiba M., Baba S. Clinical efficacy of long-term macrolides therapy for chronic sinusitis: comparison between erythromycin and clarithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 9.13.
  45. Bachand J.R.T. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother., 1991, 27 (suppl. A): 91-100.
  46. Notario G., Reitmeyer R., Horn R. Clarithromycin 250 mg BID in the treatment of patients with acute exacerbation of chronic bronchitis with COPD. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 11.06.
  47. Mehtar S., Macklin J.L., Coles S.J., et al. Clinical efficacy of clarithromycin compared with amoxicillin and cefaclor in the treatment of bronchitis. In: The 17th International Congress on Chemotherapy. Berlin, 1991.
  48. Jenkinson S., Anzueto A., Smith B., et al. Clarithromycin compared with cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992.
  49. Spiritus E., Devcich K., Drnec J., et al. Clarithromycin vs cefaclor for acute exacerbations of bronchitis. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992.
  50. Ziering W., McElvaine P., Taglieti M. Cedax (ceftibuten) in the treatment of acute exacerbation of chronic bronchitis. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995: abstr. LM39.
  51. Leophonte P., Chauvin J.P. Safety and efficacy of clarithromycin compared with cefpodoxim proxetil in the treatment of acute exacerbation of chronic obstructive pulmonary disease. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 11.05.
  52. Hosie J., Quinn P., Smits P., et al. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother., 1995, 36: 173-183.
  53. Pozzi E., Grossi E., Pecori A., et al. Azithromycin versus clarithromycin the treatment of acute exacerbations of chronic bronchitis. Curr. Ther. Res., 1994, 55: 759-764.
  54. Hara K., Hirota M., Kohno S., et al. Double-blind comparative study on TE-031 (clarithromycin) and cefaclor in the treatment of chronic respiratory tract infections. Chemotherapy, 1989, 37: 314-332.
  55. Spiritus E. Clarithromycin in the treatment of bacterial exacerbations of chronic bronchitis in smokers. Curr. Ther. Res., 1995, 56: 16-23.
  56. Craft J.C., Olson C. Clarithromycin in the treatment of lower respiratory tract infection by age. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.08.
  57. Martin R., Rank R., Persson K., et al. Chlamidia pneumoniae (TWAR): comparative efficacy of clarithromycin and erythromycin. In: The 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, 1990.
  58. Cassell G.H., Drnec J., Waites K.B., et al. Efficacy of clarithromicin against Mycoplasma pneumoniae. J. Antimicrob. Chemother., 1991, 27 (suppl. A): 47-59.
  59. Chien S., Pichotta P., Siepman N., et al. Treatment of community-acquired pneumonia: a multicenter, double-blind , randomized study comparing clarithromycin with erythromycin. Chest, 1993, 103: 697-701.
  60. Hamedani P., Hafeez S., Bachand J.R., et al. The safety and efficacy of clarithromycin in patients with Legionella pneumonia. Chest, 1991, 100: 1503-1506.
  61. Craft J.C., Stamler D. The role of clarithromycin in patients with Legionella pneumonia. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 359-362.
  62. Parola D., De Maio F., Minniti R., et al. Clarithromycin in Legionnaires disease. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 1.06.
  63. Gotfried M.H., Killian A., Servi R., et al. Oral clarithromycin vs IV erythromycin for the treatment of community-acquired pneumonia in hospitalized patients. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 12.03.
  64. Skupien D., Margulis A., Kaczander N., et al. Randomized comparative trial of the safety, efficacy and cost of intravenous (IV) cefuroxime plus erythromycin vs. IV cefuroxime plus oral clarithromycin in the therapy of community acquired pneumonia. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 12.08.
  65. Gotfried M.H., Killian A., Servi R., et al. IV cefuroxime plus oral clarithromycin or IV erythromycin for the treatment of community-acquired pneumonia in hospitalised patients: a pilot study. Clin. Drug Invest., 1997, 14: 23-34.
  66. Reinharz D., Tessier G., Laurier C., et al. Pharmacoeconomic evaluation of clarithromycin for the treatment of community-acquired pneumonia. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: Poster Session.
  67. Vogel F., Oberender P. Pharmacoeconomical evaluation: therapy with clarithromycin vs. other antibiotics in the treatment of lower respiratory tract infection. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: Poster Session.
  68. Horsburgh C.R. Advances in the prevention and treatment of Mycobacterium avium disease. N. Engl. J. Med., 1996, 335: 428-430.
  69. Shafran S.D., Singer J., Zarowny D.P., et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteriemia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N. Engl. J. Med., 1996, 335: 377-383.
  70. Cohn D.L., Fisher E., Franchino B., et al. Comparison of two doses of clarithromycin in a randomized trial of four 3-drug regimens for treatment of disseminated Mycobacterium avium complex disease in AIDS: excess mortality associated with high-dose clarithromycin. In: The 11th International Conference on AIDS. Vancouver, 1996.
  71. Wallace R.J., Tanner D., Brennan P.J., et al. Clinical trial of clarithromycin for cutaneus (disseminated) infection due to Mycobacterium chelonae. Ann. Int. Med., 1993, 119: 482-486.
  72. Dautzenberg B., Chauvin J.P. Treatment of nontuberculosis mycobacteria. The french experience with clarithromycin. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 488-496.
  73. Darmaillac V., Bouchard S., Lamouliatte H., et al. Effects of pH on susceptibility of Helicobacter pylori to macrolides. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.13.
  74. Olson C., Edmonds A. Primary susceptibility of H.pylori to clarithromycin compared to metronidazole in patients with duodenal ulcers associated with H.pylori infection. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.02.
  75. Hunt R., Schwartz H., Fitch D., et al. Dual therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with H.pylori infection. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.18.
  76. Chiba N., Wilkinson J.M., Hunt R.H. Clarithromycin or amoxicillin dual and triple therapies in H.pylori eradication: a meta-analysis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 5.26.
  77. Goodwin C.S., Mendall M.M., Northfield T. Helicobacter pylori infection. Lancet, 1997, 349: 265-269.
  78. Frevel M., Daake H., Janisch H.-D., et al. Pantoprazol + clarithromycin + metronidazol im vergleich mit pantoprazol + clarithromycin + amoxicillin zur H.pylori-eradikation. Dtsch. Ubrstz. Gastroenterol, 1997, 112 (suppl.): A119.
  79. Gupta S., Siepman N. Comparative safety and efficacy of clarithromycin versus reference agents in the treatment of mild to moderate bacterial skin or skin structure infections. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992.
  80. Parish L.C. Clarithromycin in the treatment of the skin and skin structure infections: two multicenter clinical studies. Int. J. Dermatol., 1993, 32: 528-532.
  81. Fernandes-Martin J., Leport C., Morlat P., et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob. Agents Chemother., 1991, 35: 2049-2052.
  82. Stein G.E., Mummaw N., Christensen S. Randomized trial of clarithromycin and doxycycline in the treatment of non-gonococcal urethritis/cervicitis. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992: abstr. 257.
  83. Ito Y., Komeda H., Kobayashi K., et al. TE-031 (A-56268) against gonococcal and non-gonococcal urethritis. Chemotherapy, 1988, 36: 832-837.
  84. Yanagi F., Kusama M., Tanaka K., et al. TE-031 (A-56268) in acute dental infections in the stomatognathic area. Chemotherapy, 1988, 36: 1086-1090.
  85. Sasaki J., Morishima T., Sakamoto H., et al. Clinical evaluation of clarithromycin in the treatment of acute dental infections. Jap. J. Antib., 1989, 42: 983-1013.
  86. Hatano H., Wakamatsu K. TE-031 (A-56268) In ophthalmology. Chemotherapy, 1988, 36: 1109-1113.
  87. Pierce M., Crampton S., Henry D., et al. A randomized trial of clarithromycin as prophilaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med., 1996, 335: 384-391.
  88. Crampton S., Craft J.C., Notario G., et al. Prevention of Pneumocystis carinii pneumonia in AIDS patients by clarithromycin prophylaxis for Mycobacterium avium complex. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 7.09.
  89. Schaad U., Siepman N., Northcutt V.J., et al. Clarithromycin in pediatric patients. In: The 1st International Conference on the Macrolides, Azalides and Streptogramins. Santa Fe, 1992.
  90. Coles S.J., Macklin J.M., Addlestone M.B., et al. Clarithromycin versus amoxicillin suspensions in the treatment of acute otitis media in children. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 451-455.
  91. Kafetzis D.A., Malaka-Zafiriou C., Bairamis T., et al. Comparison of the efficacy and tolerability of clarithromycin suspension and cefuroxim axetil suspension in the treatment of acute otitis media in paediatric patients. Clin. Drug Invest., 1997, 14: 192-199.
  92. Hedrick J., Gooch M., Kaplan E. A short course of clarithromycin suspension vs. penicillin V suspension in children with streptococcal pharyngitis. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. LM-26.
  93. Ramet J. A comparative safety and efficacy of clarithromycin and azithromycin in the short course treatment of children with acute otitis media. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 10.09.
  94. Scholz H., Study Group Collegues. Study of the efficacy and toleration of clarithromycin suspension in children with acute otitis media. Pediatrician, 1996, 27: 540-542.
  95. Tachibana F., Hiraga S., Ishida T., et al. Clinical efficacy of clarithromycin therapy for chronic sinusitis and secretory otitis media in children. Jibi to Rinsho, 1994, 87: 421-427.
  96. Toyonaga Y. Clinical and bacteriological evaluation of clarithromycin 50 mg tablets in children with lower respiratory tract infection. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.10.
  97. Macklin J.L., Coles S.J. Safety and efficacy of clarithromycin compared with amoxicillin or cefaclor in children with lower respiratory tract infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 394-398.
  98. Zarkovic J., Haider-Salaberger I. Efficacy and safety of clarithromycin compared with amoxicillin/clavulanic acid in children with lower respiratory tract infections. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 13.12.
  99. Block S., Hedrick J., Hammerschlag R., et al. Mycoplasma pneumoniae and Chlamidia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr. Infect. Dis. J., 1995, 14: 471-477.
  100. Delollis R.D., Kundsin R.B., Poulin S. Could clarithromycin prevent asthma? In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.19.
  101. Berger C.H., Pfyffer G.E., Nadal D. Drug therapy of lymphadenitis with non-tuberculious Mycobacteria. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 7.22.
  102. Kwok-Woon Y., Neu H.C. In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics. Antimicrob. Agents Chemother., 1990, 34: 1839-1842.
  103. Grayson M.L., Eliopoulos G.M., Ferraro M.J., et al. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8 (suppl. 10): 888-889.
  104. Brogden R.N., Peters D.H. Dirithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 1994, 48: 599-616.
  105. Segreti J., Kapell K. In vitro activity of dirithromycin against Chlamydia trachomatis. Antimicrob. Agents Chemother., 1994, 38: 2213-2214.
  106. Bryskier A., Labro M. Macrolides, nouvelles perspectives therapeutiques. Pres. Med., 1994, 23: 1762-1766.
  107. Orfila J., Haider F., Bryskier A. In vitro activity of eleven macrolides and pristinamycin against Chlamidia psittaci. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 151.
  108. Baughman R.P., De Sante K.A., Lanier T.L., et al. The penetration of dirithromycin into bronchoalveolar lavage fluid and alveolar macrophages. J. Antimicrob. Chemother., 1994, 33: 1045-1050.
  109. Delatour F., Faurisson F., Rouveix B. Evaluation of anti-inflammatory activity of dirithromycin in a lung inflammation murine model. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 9.01.
  110. Bergogne-Berezin E. Tissue distribution of dirithromycin: comparison with erythromycin. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 77-87.
  111. Cazzola M., Tufano M.A., Polverino M., et al. Pulmonary penetration of dirithromycin in chronic bronchitis. In: 6th European Congress of Clinical Microbiology and Infectious Diseases. Seville, 1993: abstr. 320.
  112. Muller-Serieys C., Lemaitre F., Derriennic M., et al. Penetration of dirithromycin in tonsillar tissue: a multiple dose study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.11.
  113. Hand W.L., Hand D.L. Interactions of dirithromycin with human polymorphonuclear leukocytes. Antimicrob. Agents Chemother., 1993, 37: 2557-2562.
  114. Sides G.D., Cerimele B.J., Black H.R., et al. Pharmacokinetics of dirithromycin. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 65-75.
  115. LaBrecque D.R., Geraets D., Johlin F.C., et al. Biliary elimination of dirithromycin following single-dose administration. In: The 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, 1992: abstr. 748.
  116. Ripley E.D., Sica D.A., Gehr T.W., et al. Dirithromycin pharmacokinetics in hemodialysis and chronic renal failure. Clin. Pharmacol. Ther., 1992, 51:137.
  117. Sides G.D., Conforti P.M. Safety profile of dirithromycin J. Antimicrob. Chemother., 1993, 31 (suppl. C): 175-185.
  118. Jacobson K. Clinical efficacy of dirithromycin in pneumonia. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 121-129.
  119. Liippo K., Tala E., Puolijoki H., et al. A comparative study of dirithromycin and erythromycin in bacterial pneumonia. J. Infect., 1994, 28: 131-139.
  120. Derriennic M., Conforti P.M., Sides G.D. Dirithromycin in the treatment of streptococcal pharyngitis. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 89-95.
  121. Lindstrom T.D., Hanssen B.R., Wrighton S.A. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob. Agents Chemother., 1993, 37: 265-269.
  122. McCarty J.M., Huck W., Guthrie E.H., et al. Dirithromycin vs. penicillin VK in the treatment of streptococcal pharyngitis and/or tonsillitis. In: The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1993: abstr. 399.
  123. Muller 0., Wettich K. Clinical efficacy of dirithromycin in pharyngitis and tonsillitis. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 97-102.
  124. Sides G.D. Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother., 1993, 31 (suppl. C): 131-138.
  125. Cazzola M., Santangelo G., Vingiguerra A., et al. A five-day course of dirithromycin in the treatment of acute exacerbation of chronic bronchitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 11.01.
  126. Leroyer C., Muller-Serieys C., Quiott J.J., et al. High dirithromycin tissue concentrations and clinical efficacy in acute exacerbations of chronic bronchitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.10.
  127. Dilorenzo P., Shupbach C., Salisbury J., et al; Dirithromycin in the treatment of skin and skin structure infections. In: The 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1993: abstr. 402.
  128. Varanese L., Sides G. Dirithromycin efficacy in skin and skin structure infections. In: The 2th International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 308.
  129. Meloni F., Ballabio P., Gorrini M., et al. Anti-inflammatory effects of flurithromycin and erythromycin. In: European Respiratory Society. Annual Congress. Berlin, 1997: abstr. P0438.
  130. Cocuza C.E., Mattina R., Lanzafame A., et al. Serum levels of flurithromycin ethylsuccinate in healthy volunteers. Chemotherapy, 1994, 40: 157-160.
  131. Bariffi F., Clini V., Ginesu F., et al. Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections. Infection, 1994, 22: 226-230.
  132. Agouridas C., Bonnefoy A., Chantot J.F. In vitro antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1995: abstr. F156.
  133. Agouridas C., Bonnefoy A., Chantot J.F. In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. F123.
  134. Jones R.N., Biedenbach D.J. In vitro evaluation of a novel ketolide antimicrobial agent, RU 64004. Diagn. Microbiol. Infect. Dis., 1997, 27: 7-12.
  135. Djokic S., Kobrehel G., Lazarevski G. Antibacterial in vitro evaluation of 10-dihydro-l0-deoxo-11-azaerythromycin A: synthesis and structure activity relationship of its acyl derivatives. J. Antibiot., 1987, 40: 1006-1015.
  136. Scorneaux B., Ouadrhiri Y., Anzalone G., et al. Intracellular activity of azithromycin in relation to its cellular disposition towards bacteria infecting distinct subcellular compartments. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.17.
  137. Ridgway G.L. In vitro activity against Mycoplasma spp. and intracellular organisms. In: New Macrolides, Azalides, and Streptogramins - Pharmacology and Clinical Applications. Neu H.C., Young L.S., Zinner S.H. (Eds.). New York, etc., 1993: 25-30.
  138. Keysary A., Itzhaki A., Rubinstein E., et al. The in vitro antiricketsial activity of macrolides. J. Antimicrob. Chemother., 1996, 38: 727-731.
  139. Rehg J.E. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosupressed rats. J. Infect. Dis., 1994, 170: 934-938.
  140. Knight S., Paul T., Raulston J., et al. Delivery of biologically active azithromycin migrating polymorphonuclear leukocytes to and killing of chlamydia in infected polarized human epithelia. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.02.
  141. Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother., 1990, 25 (suppl. A): 73-82.
  142. Wildfeuer A., Laufen H., L:eitold M., et al. Comparison of pharmacokinetics of three-day and five-day regimens azithromycin in plasma and urine. J. Antimicrob. Chemother., 1993, 31: 51-56.
  143. Thakker K.M., Caridi F., Powell M., et al. Multiple dose pharmacokinetics of azithromycin following 1 hour intravenous infusions in hospitalized patients with community acquired pneumonia. In: The 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 1997: abstr. A-118.
  144. Vaudaux B.P., Cherpillod J., Dayer P. Tonsillar/adenoid tissue concentrations of azithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.12.
  145. Foulds G., Johnson R.B. Selection of dose regimens of azithromycin. J. Antimicrob. Chemother., 1993, 31 (suppl. E): 39-50.
  146. Coates P., Daniel R., Houston A.C., et al. An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers. Eur. J. Clin. Microbiol. Infect. Dis., 1991, 10: 850-852.
  147. Тихонов В.Г. Бактериологическое фармакокинетическое обоснование применения макролидных антибиотиков при гнойных гайморитах. Автореф. канд. дисс. - М., 1995.
  148. Wise R., Andrews J.M., Honeybourne D., et al. The penetration of azalides and macrolides into the respiratory tract. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 193.
  149. Olsen K.M., San Pedro G.S., Gann L.P., et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.09.
  150. Karma P., Pukander J., Penttila М., et al. The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis. J. Antimicrob. Chemother., 1991, 27 (suppl. A): 83-90.
  151. Pukander J. Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 199
  152. Onodera S., Shiba K. Tissue and body fluid concentrations of azithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.14.
  153. LeBel М., Bisson S., Allard S., et al. Prostatic fluid and ejaculate penetration of single 1 g dose azithromycin. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 201.
  154. Strachunsky L., Firsov A., Dombrovsky V., et al. Azithromycin penetration into human seminal fluid. In: The 2th International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 202.
  155. LeBel М., Gregoire М., Vallee F., et al. Prostate tissue concentrations following a single 1 gm dose of azithromycin. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.15.
  156. Worm A.-M., Osterling A. Azithromycin levels in cervical mucous and plasma after a single oral dose. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice, 1994: abstr. 200.
  157. Мариновичев И.А. Клинико-фармакокинетическое обоснование лечения острых хламидийных уретритов у мужчин макролидными антибиотиками. Автореф. канд. дисс. - Смоленск, 1995.
  158. Stray-Pederson В. The European Research Network on Congenital Toxoplasmosis Treatment Group. Azithromycin levels in placental tissue, amniotic fluid and blood. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. A68.
  159. Girard A.E., Cimochowski C.R., Faiella J.A. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J. Antimicrob. Chemother., 1996, 37 (suppl. С): 9-19.
  160. Takahashi K., Duchateau V., Husson М., et al. A human model of local abscess using skin chambers: penetration of azithromycin and the chemiluminescence response of neutrophil. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 4.16.

© 2000-2007 НИИАХ СГМА Rambler's Top100 TopList Rambler's Top100